Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
1.
Front Public Health ; 11: 1167321, 2023.
Article in English | MEDLINE | ID: covidwho-20234130

ABSTRACT

Background: Prior to COVID-19 pandemic, a yearly upward trajectory in the number of chlamydia infection cases was observed in South Korea. However, in response to the COVID-19 pandemic, Korea implemented several public health and social measures, which were shown to have an impact on the epidemiology of other infectious diseases. This study aimed to estimate the impact of the COVID-19 pandemic on the incidence and number of reported chlamydia infections in South Korea. Methods: Using the monthly number of reported chlamydia infection data between 2017 and 2022, we compared the trends in the reported numbers, and the incidence rates (IR) of chlamydia infection stratified by demographic characteristics (sex, age group, and region) in the pre- and during COVID-19 pandemic period (January 2017-December 2019 and January 2020-December 2022). Results: We observed an irregular downward trajectory in the number of chlamydia infection in the during-pandemic period. A 30% decrease in the total number of chlamydia infection was estimated in the during-pandemic compared to the pre-pandemic period, with the decrease greater among males (35%) than females (25%). In addition, there was a decrease in the cumulative incidence rate of the during COVID-19 pandemic period (IR: 0.43; 95% CI: 0.42-0.44) compared to the pre-pandemic period (IR: 0.60; 95% CI: 0.59-0.61). Conclusions: We identified decrease in the number of chlamydia infection during COVID-19 pandemic which is likely due to underdiagnosis and underreporting for the infection. Therefore, strengthening surveillance for sexually transmitted infections including chlamydia is warranted for an effective and timely response in case of an unexpected rebound in the number of the infections.


Subject(s)
COVID-19 , Chlamydia Infections , Gonorrhea , Male , Female , Humans , Pandemics , Gonorrhea/diagnosis , Gonorrhea/epidemiology , COVID-19/epidemiology , Chlamydia Infections/epidemiology , Republic of Korea/epidemiology
2.
Sex Transm Dis ; 50(8): 536-542, 2023 08 01.
Article in English | MEDLINE | ID: covidwho-2325606

ABSTRACT

BACKGROUND: Shifts in public health infrastructure to respond to one emerging health threat may have unanticipated consequences for preexisting diseases. Previous research evaluating the impact of COVID-19 on sexually transmitted infections (STIs) has been conducted nationally, with little exploration of the impact on a granular geospatial level. This ecological study seeks to quantify the association between COVID-19 cases or deaths and chlamydia, gonorrhea, and syphilis cases for all US counties in 2020. METHODS: Separate, adjusted multivariable quasi-Poisson models with robust standard errors modeled the county-level association between 2020 COVID-19 cases and deaths per 100,000 and 2020 chlamydia, gonorrhea, or syphilis cases per 100,000. Models were adjusted for sociodemographic characteristics. RESULTS: Every 1000 additional COVID-19 cases per 100,000 was associated with a 1.80% increase in the average number of chlamydia cases ( P < 0.001) and a 5.00% increase in the average number of gonorrhea cases ( P < 0.001). Every 1000 additional COVID-19 deaths per 100,000 was associated with a 57.9% increase in the average number gonorrhea cases ( P < 0.001) and a 74.2% decrease in the average number of syphilis cases ( P = 0.004). CONCLUSIONS: Higher rates of COVID-19 cases and deaths were associated with increased rates of some STIs at the US county level. The underlying reasons for these associations could not be established by this study. The emergency response to an emerging threat may have unanticipated influence on preexisting diseases that varies by level of governance.


Subject(s)
COVID-19 , Chlamydia Infections , Gonorrhea , HIV Infections , Sexually Transmitted Diseases , Syphilis , United States/epidemiology , Humans , Gonorrhea/epidemiology , Syphilis/epidemiology , Chlamydia Infections/epidemiology , COVID-19/epidemiology , Sexually Transmitted Diseases/epidemiology
3.
Sex Transm Dis ; 50(8): 543-549, 2023 08 01.
Article in English | MEDLINE | ID: covidwho-2299988

ABSTRACT

BACKGROUND: The COVID-19 pandemic has disrupted HIV and sexually transmitted infection (STI) testing accessibility. We sought to assess the longer-term impacts of COVID-19 on HIV and STI testing and diagnosis in Oregon. METHODS: First, we examined HIV, Neisseria gonorrhoeae / Chlamydia trachomatis (CT), and syphilis tests conducted at the Oregon State Public Health Laboratory (public sector) and a large commercial laboratory (private sector) and HIV, N. gonorrhoeae , CT, and primary and secondary (P&S) syphilis diagnoses in Oregon from January 1, 2019, to December 31, 2021. We compared monthly testing and diagnosis rates in 5 prespecified periods: pre-COVID-19 (January 2019-February 2020), stay-at-home order (March 2020-May 2020), reopening (June 2020-December 2020), vaccine availability (January 2021-June 2021), and Delta/early Omicron spread (July 2021-December 2021). Second, we calculated the number of HIV and STI diagnoses per test in the public and private sectors. Finally, we used seasonal autoregressive integrated moving average models to predict expected HIV and STI diagnoses for comparison to those observed. RESULTS: Both public and private sector HIV and bacterial STI testing fell to nadirs in April 2020 with incomplete recovery to 2019 levels by the close of 2021. Compared with pre-COVID-19, public sector and private sector testing was significantly lower in all subsequent periods. Compared with pre-COVID-19, P&S syphilis cases were 52%, 75%, and 124% greater in the reopening, vaccine availability, and Delta/early Omicron periods, respectively. From March 2020 to December 2021, we observed an excess of P&S syphilis cases (+37.1%; 95% confidence interval, 22.2% to 52.1%) and a deficit in CT cases (-10.7%; 95% confidence interval, -15.4% to -6.0%). CONCLUSIONS: By December 2021, HIV/STI testing had not recovered to pre-COVID-19 levels, and HIV/STI continues to be underdiagnosed. Despite decreased testing, P&S syphilis cases have increased substantially.


Subject(s)
COVID-19 , Chlamydia Infections , Gonorrhea , HIV Infections , Sexually Transmitted Diseases , Syphilis , Humans , Syphilis/diagnosis , Syphilis/epidemiology , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , HIV Infections/diagnosis , HIV Infections/epidemiology , Gonorrhea/diagnosis , Gonorrhea/epidemiology , Oregon/epidemiology , Pandemics , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology , COVID-19/diagnosis , COVID-19/epidemiology , Neisseria gonorrhoeae , Chlamydia trachomatis , Prevalence
4.
Sex Health ; 20(2): 105-117, 2023 04.
Article in English | MEDLINE | ID: covidwho-2303035

ABSTRACT

BACKGROUND: Young men who have sex with men (MSM) are a key population at high risk of sexually transmitted infections (STIs). We conducted a respondent-driven sampling (RDS) bio-behavioural survey to estimate the prevalence of five curable STIs: chlamydia, gonorrhoea, syphilis, trichomoniasis and Mycoplasma genitalium infection, and associated risk factors among tertiary student MSM (TSMSM) in Nairobi, Kenya. METHODS: Between February and March 2021, we recruited 248 TSMSM aged ≥18years who self-reported engaging in anal and/or oral sex with another man in the past year. Samples collected included urine, anorectal and oropharyngeal swabs for pooled Chlamydia trachomatis , Mycoplasma genitalium , Neisseria gonorrhoeae and Trichomonas vaginalis testing using multiplex nucleic acid amplification tests, and venous blood for serological Treponema pallidum screening and confirmation of current infection. Participants self-completed a behavioural survey on a REDCap digital platform. Data analysis was done using RDS-Analyst (v0.72) and Stata (v15). Differences in proportions were examined using the chi-squared (χ 2 ) test, and unweighted multivariate logistic regression was used to assess factors associated with STI prevalence. RESULTS: RDS-adjusted prevalence rates of at least one of the five STIs, chlamydia, gonorrhoea, Mycoplasma genitalium infection, trichomoniasis and latent syphilis were 58.8%, 51.0%, 11.3%, 6.0%, 1.5% and 0.7%, respectively. Factors independently associated with STI prevalence were inconsistent condom use (adjusted odds ratio (AOR)=1.89, 95% confidence interval (CI): 1.03-3.47, P =0.038) and the last sex partner being a regular partner (AOR=2.35, 95% CI: 1.12-4.92, P =0.023). CONCLUSION: STI prevalence among TSMSM in Nairobi, Kenya, is disturbingly high, demonstrating urgent need for tailored testing, treatment and prevention interventions for this population.


Subject(s)
Chlamydia Infections , Gonorrhea , Mycoplasma Infections , Mycoplasma genitalium , Sexual and Gender Minorities , Sexually Transmitted Diseases , Syphilis , Trichomonas Infections , Male , Humans , Homosexuality, Male , Gonorrhea/epidemiology , Gonorrhea/diagnosis , Syphilis/epidemiology , Prevalence , Kenya/epidemiology , Mycoplasma Infections/epidemiology , Mycoplasma Infections/diagnosis , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/diagnosis , Risk Factors , Neisseria gonorrhoeae , Surveys and Questionnaires , Trichomonas Infections/epidemiology , Chlamydia Infections/epidemiology , Chlamydia Infections/diagnosis
6.
Sex Transm Dis ; 50(7): 415-419, 2023 Jul 01.
Article in English | MEDLINE | ID: covidwho-2262516

ABSTRACT

BACKGROUND: National guidelines recommend sexually active women younger than 25 years be screened annually for chlamydia. Our objective was to estimate the chlamydia screening rate of sexually active women aged 16 to 24 years from 2011 to 2020. METHODS: We analyzed the chlamydia screening rates among sexually active women aged 16 to 24 years from 2011 to 2020 using the chlamydia measures in the Healthcare Effectiveness Data and Information Set data set. The annual national chlamydia screening rates were further stratified by census region and by patient age. RESULTS: Chlamydia screening rates among sexually active women aged 16 to 24 years ranged from 55.0% to 61.8% in Medicaid health plans and from 46.9% to 52.4% in commercial health plans during 2011-2020. The Northeast consistently had the highest screening rates among 4 geographic regions. The chlamydia screening rate among sexually active women aged 16 to 24 years decreased from 2019 to 2020: from 61.8% to 57.9% in Medicaid plans and from 52.4% to 48.4% in commercial health plans. The number of sexually active women aged 16 to 24 years covered by commercial health plans decreased from 2019 to 2020, but the number covered by Medicaid increased from 2019 to 2020. CONCLUSIONS: The chlamydia screening rates in the target population have increased little from 2011 to 2019. The decrease in chlamydia screening rates between 2019 and 2020 could be related to the COVID-19 pandemic and the reduced use of health services during that period. With recently suboptimal chlamydia screening rates in the United States, interventions of improving and assessing chlamydia screening rates are needed.


Subject(s)
COVID-19 , Chlamydia Infections , United States/epidemiology , Female , Humans , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology , Chlamydia Infections/prevention & control , Pandemics , COVID-19/diagnosis , COVID-19/epidemiology , Medicaid , Chlamydia trachomatis , Mass Screening
7.
AIDS Patient Care STDS ; 37(4): 199-204, 2023 04.
Article in English | MEDLINE | ID: covidwho-2268516

ABSTRACT

HIV and other sexually transmitted infections (STIs) are on the rise nationally and internationally. The coronavirus 2019 (COVID-19) pandemic drove a shift toward telemedicine and prioritization of symptomatic treatment over asymptomatic screening. The impact in safety-net settings, which faced disproportionate baseline STI/HIV rates rooted in structural inequities, and where many patients lack telemedicine resources, is not yet known. This study describes the impact of COVID-19 on STI/HIV testing at an urban safety-net hospital. We used descriptive statistics to compare hospital-wide chlamydia, gonorrhea, syphilis, and HIV testing volume and positivity rates in the following periods: prepandemic (July 1, 2019-February 29, 2020), peak-pandemic (March 1, 2020-May 31, 2020), and postpeak (June 1, 2020-August 31, 2021). STI and HIV test volume dropped sharply in March 2020. STI testing during the peak-pandemic period was 42% of prepandemic baseline (mean 1145 vs. 2738 tests/month) and nadired in April 2020 (766 tests/month). Similarly, peak-pandemic HIV testing was 43% of prepandemic baseline (mean 711 vs. 1635 tests/month) and nadired in April 2020 with 438 tests/month, concentrated in emergency department and inpatient settings. STI and HIV testing rates did not return to baseline for a full year. STI and HIV test positivity rates were higher in the peak-pandemic period compared with the prepandemic baseline. Given the precipitous decline in STI and HIV testing during the pandemic, safety-net settings should develop low-barrier alternatives to traditional office-based testing to mitigate testing gaps, high positivity rates, and associated morbidity.


Subject(s)
COVID-19 , Chlamydia Infections , Gonorrhea , HIV Infections , Sexually Transmitted Diseases , Syphilis , Humans , HIV Infections/diagnosis , HIV Infections/epidemiology , HIV Infections/prevention & control , Safety-net Providers , COVID-19/diagnosis , COVID-19/epidemiology , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/prevention & control , Gonorrhea/diagnosis , Syphilis/diagnosis , HIV Testing , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology , Mass Screening
8.
Swiss Med Wkly ; 152: w30102, 2022 01 03.
Article in English | MEDLINE | ID: covidwho-2263904

ABSTRACT

Zoonotic species of the Chlamydiaceae family should be considered as rare pathogenic agents of severe atypical pneumonia. A fatal case of a severe pneumonia due to Chlamydia psittaci was traced back to pet birds, and pneumonia in a pregnant woman was attributed to abortions in a sheep and goat flock, being the source of Chlamydia abortus. The two SARS­CoV­2-negative pneumonia cases presented here were investigated in an inter-disciplinary approach involving physicians and veterinarians. State-of-art molecular methods allowed the identification and genotyping of zoonotic Chlamydiae.


Subject(s)
COVID-19 , Chlamydia Infections , Chlamydophila psittaci , Animals , Birds , Chlamydia Infections/complications , Chlamydia Infections/diagnosis , Chlamydophila psittaci/genetics , Female , Humans , Pregnancy , SARS-CoV-2 , Sheep
9.
researchsquare; 2023.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2759920.v1

ABSTRACT

Objective To analyze the epidemic trend of respiratory pathogens under non-pharmaceutical interventions during the COVID-19 pandemic in Guangzhou and to explore the causes. Methods Respiratory pathogens, namely influenza A virus (FluA), influenza B virus (FluB), respiratory syncytial virus (RSV), human parainfluenza virus (PIV), adenovirus (AdV), Mycoplasma pneumoniae (MP) and Chlamydia pneumoniae (Cpn), were selected from a total of 14549 patients from December 1, 2019 to November 30, 2022. The differences in the positive constituent ratios and detection rates of each pathogen were analyzed and compared among different years, ages, genders, and seasons. Results The detection rate of RSV (1.03%) was higher than that of FluA (0.42%), PIV (0.41%), MP (0.23%), AdV (0.10%), FluB (0.06%) and Cpn (0.01%), and the difference was statistically significant. There was a statistically significant difference between two comparisons of the detection rates of FluA in different years, with the lowest in 2021 (0%) and the highest in 2022 (1.32%). The detection rate of RSV in 2021 (0.80%) showed a decreasing trend compared to 2020 (1.43%). FluA replaced RSV in 2020 and 2021 as the dominant strain in 2022. The detection rates of RSV (5.21%), PIV (1.88%) and AdV (0.47%) in children were higher than those of 0.97%, 0.44% and 0.09% in young and middle-aged adults, respectively. They were also higher than 0.20%, 0.10% and 0.03% in the elderly, respectively, with statistically significant differences. The detection rate of FluA in children (0.89%) was higher than that in the elderly (0.36%), with a statistically significant difference. There was a statistically significant difference in the detection rates of RSV and PIV between young and middle-aged adults and the elderly. RSV was the predominant strain in both children and young and middle-aged adults, but it was replaced by FluA in the elderly. The detection rates of RSV (1.31%) and PIV (0.58%) were higher in female than in male (0.88% and 0.32%, respectively), and the differences were statistically significant. The predominant strain in both male and female was RSV. There were seasonal differences in the detection rates of FluA, RSV and PIV. The detection rate of FluA was highest in summer (1.34%), followed by winter (0.47%), spring and autumn were lowest, both were 0%. The detection rate of RSV was highest in autumn (2.19%), followed by summer (1.32%), spring and winter were lower (0.32% and 0.45%, respectively). The detection rate of PIV was highest in winter (1.01%), and 0.16%, 0.23%, and 0.21% in spring, summer, and autumn, respectively. The dominant strain was RSV in spring, summer and autumn, which was replaced by PIV in winter. Among the 13,270 patients who were screened for all seven of these pathogens simultaneously, the top four pathogen-positive composition ratios were RSV (41.54%), FluA (21.15%), PIV (18.46%) and MP (10.38%). Single pathogen infection was dominated by RSV infection, accounting for 0.81%, and two pathogen infections were dominated by FluA+PIV and RSV+ MP infection, with one case each. Conclusions RSV was more prevalent and Cpn was less common among respiratory pathogens infections in Guangzhou under non-pharmacological intervention during the New Coronavirus-19 pandemic. Annual differences existed in the detection rates of FluA and RSV. The detection rates of RSV and PIV were highest in children, followed by  young and middle-aged adults, and the elderly. The detection rates of RSV and PIV were higher in females than in males. There were seasonal differences in the detection rates of FluA, RSV and PIV, with the highest detection rates of FluA in summer, RSV in autumn and PIV in winter. Infection patterns were more common with single pathogens. The predominant strain was mostly RSV, except in 2022 and in the elderly was replaced by FluA, and was replaced by PIV in winter.


Subject(s)
COVID-19 , Respiratory Syncytial Virus Infections , Chlamydia Infections , Pneumonia, Mycoplasma
10.
medrxiv; 2023.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2023.03.22.23287571

ABSTRACT

Purpose: Measures to control COVID-19 reduced face-to-face appointments and walk-ins at sexual health services (SHSs). Remote access to SHSs through online self-sampling for STIs was increased. This analysis assesses how these changes affected service use and STI testing among young people in England. Methods: Data on all chlamydia, gonorrhoea and syphilis tests from 2019-2020 amongst English-resident 15-24 year olds (hereafter referred to as young people) were obtained from national STI surveillance datasets. We calculated proportional differences in tests and diagnoses for each STI, by demographic characteristics including age and socioeconomic deprivation, between 2019 and 2020. Among those tested for chlamydia, we used binary logistic regression to determine crude and adjusted odds ratios (OR) between demographic characteristics and being tested for chlamydia by an online service. Results: Compared to 2019, there were declines in testing (30% for chlamydia, 26% for gonorrhoea, 36% for syphilis) and diagnoses (31% for chlamydia, 25% for gonorrhoea and 23% for syphilis) among young people in 2020. These reductions were greater amongst 15-19 year-olds (vs. 20-24 year-olds). Among young people tested for chlamydia, those living in the least deprived areas were more likely to be tested using an online self-sampling kit compared to those living in the most deprived areas (males; OR=1.24[1.22-1.26], females; OR=1.28[1.27-1.30]). Conclusion: The first year of the COVID-19 pandemic in England saw declines in STI testing and diagnoses in young people and disparities in the use of online chlamydia self-sampling which risk widening existing health inequalities.


Subject(s)
COVID-19 , Chlamydia Infections , Pulmonary Disease, Chronic Obstructive
11.
Sex Transm Dis ; 50(8S Suppl 1): S53-S56, 2023 08 01.
Article in English | MEDLINE | ID: covidwho-2222915

ABSTRACT

ABSTRACT: Disease intervention specialists are often at the forefront of adoption of new technologies in support of sexually transmitted infection (STI) contact tracing efforts. Newer technology for detection of treatable STI includes point-of-care molecular tests for detection of chlamydia, gonorrhea, and trichomonas and syphilis serology point-of-care tests. Other additions to our case finding toolbox are the use of telemedicine and the proliferation of direct-to-consumer offerings, both of which rely on remote sample collection involving self-collection of specimens in nonclinical settings. Finally, on the near horizon are over-the-counter tests that will support self-testing without the involvement of a medical professional. Each of these new developments is discussed and contextualized in experiences resulting from the COVID-19 pandemic response. Many options are now available, or will be soon, for detection of STIs in nontraditional settings, and we need to consider the processes involved as we move toward adoption of these new tools.


Subject(s)
COVID-19 , Chlamydia Infections , Gonorrhea , HIV Infections , Sexually Transmitted Diseases , Syphilis , Humans , Pandemics , Chlamydia Infections/diagnosis , COVID-19/diagnosis , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/prevention & control , Sexually Transmitted Diseases/epidemiology , Gonorrhea/epidemiology , HIV Infections/epidemiology , Syphilis/epidemiology
12.
Schweiz Arch Tierheilkd ; 165(1): 59-63, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2204330

ABSTRACT

INTRODUCTION: In a guinea pig herd with 26 breeding animals, several individuals of all age categories died (16/26) after three animals had been newly introduced from another herd. Furthermore, the population suffered of apathy, anorexia, severe weight loss and conjunctivitis, as well as abortions and stillbirths. At the same time, the owner experienced a SARS-CoV-2 infection with pneumonia, which was confirmed by taking a PCR test. Chlamydia caviae was detected from the conjunctiva and vagina/uterus in one juvenile animal together with an intestinal Cryptosporidium wrairi infection. Oocysts were found histologically in the small intestine, which was confirmed by PCR. C. wairi is a parasite adapted to guinea pigs with zoonotic potential, which causes diarrhoea with frequent deaths in larger guinea pig herds. C. caviae is also a zoonotic pathogen and often the cause of conjunctivitis, pneumonia and abortions in guinea pigs and can lead to upper respiratory tract disease, conjunctivitis but also severe pneumonia in humans. The increased death cases and the clinical signs could be traced back to an infection with Cryptosporidium wrairi, complicated by a co-infection of C. caviae. We suspect that the abortions were caused by C. caviae, but since the population was treated with various antibiotics effective against chlamydial infections, it was no longer possible to verify this by PCR testing. Unfortunately, more animals succumbed and finally only two animals of the originally 26 were left. With this case report, we would like to point out to veterinarians that guinea pigs can be an important source of zoonotic infections for various pathogens, especially since they are popular pets and often come into close contact with children where hygiene might not always be strictly followed.


INTRODUCTION: Dans un groupe de cobayes de 26 animaux reproducteurs, plusieurs individus de toutes les catégories d'âge sont morts (16/26) après l'introduction de trois animaux provenant d'un autre groupe. En outre, la population a souffert d'apathie, d'anorexie, de perte de poids sévère et de conjonctivite ainsi que d'avortements et de mortinatalité. La présence de Chlamydia caviae a pu être détectée dans la conjonctive et le vagin/utérus d'un animal juvénile, ainsi qu'une infection intestinale à Cryptosporidium wrairi. Des oocystes ont été trouvés histologiquement dans l'intestin grêle, ce qui a été confirmé par PCR. C. wairi est un parasite adapté aux cobayes avec un potentiel zoonotique, qui provoque des diarrhées avec des morts fréquentes dans les grands groupes de cobayes. C. caviae est également un agent pathogène zoonotique et est souvent à l'origine de conjonctivites, de pneumonies et d'avortements chez les cobayes ; il peut entraîner des maladies des voies respiratoires supérieures, des conjonctivites mais aussi des pneumonies graves chez l'homme. L'augmentation des cas de décès et les signes cliniques pourraient être attribués à une infection par Cryptosporidium wrairi, compliquée par une co-infection par C. caviae. Nous soupçonnons que les avortements ont été causés par C. caviae, mais comme la population a été traitée avec divers antibiotiques efficaces contre les infections à chlamydia, il n'était plus possible de le vérifier par des tests PCR. Malheureusement, d'autres animaux ont succombé et il ne restait finalement que deux animaux sur les 26 d'origine. Avec ce rapport de cas, nous aimerions attirer l'attention des vétérinaires sur le fait que les cochons d'Inde peuvent être une source importante d'infections zoonotiques pour divers pathogènes, d'autant plus qu'il s'agit d'animaux de compagnie populaires qui sont souvent en contact étroit avec des enfants avec lesquels l'hygiène n'est pas toujours strictement respectée.


Subject(s)
Chlamydia Infections , Conjunctivitis , Cryptosporidiosis , Guinea Pigs , Animals , Female , Humans , Conjunctivitis/epidemiology , Conjunctivitis/microbiology , Conjunctivitis/parasitology , Conjunctivitis/veterinary , Cryptosporidiosis/epidemiology , Cryptosporidium , Disease Outbreaks/veterinary , Chlamydia Infections/complications , Chlamydia Infections/epidemiology , Chlamydia Infections/veterinary , Zoonoses/epidemiology , Zoonoses/microbiology , Zoonoses/parasitology
13.
Euro Surveill ; 27(39)2022 09.
Article in English | MEDLINE | ID: covidwho-2054866

ABSTRACT

BackgroundDiagnoses of bacterial sexually transmitted infections (STIs) have increased in France since the 2000s. The main strategy to control STI transmission is recommending/facilitating access to condom use, testing, and antibiotic treatments.AimThis study analyses the evolution of STI testing in the private sector in France from 2006 to 2020.MethodsNational health insurance reimbursement data were used to determine numbers and rates of individuals aged ≥ 15 years tested for diagnoses of chlamydia, gonorrhoea and syphilis in the private sector in France and to describe their evolution from 2006 to 2020.ResultsUpward tendencies in testing were observed from 2006 to 2019 for all three STIs. The highest testing rates were identified in people aged 25‒29-years old. The observed testing-increase from 2017 to 2019 was twice as high in young people (< 25 years old) as in older people. In 2019, chlamydia, gonorrhoea and syphilis testing rates were respectively 45.4 (+ 21% since 2017), 41.3 (+ 60%), and 47.2 (+ 22%) per 1,000 inhabitants. For all STIs combined, the number of tested individuals decreased by 37% between March and April 2020 during the first COVID-19 epidemic wave and lockdown in France.ConclusionImprovements found in STI testing rates may have resulted from better awareness, especially among young people and health professionals, of the importance of testing, following prevention campaigns. Nevertheless, testing levels remain insufficient considering increasing diagnoses. In 2020, the COVID-19 pandemic had a considerable impact on STI testing. Partner notification and offering diverse testing opportunities including self-sampling are essential to control STI epidemics particularly in exposed populations.


Subject(s)
COVID-19 , Chlamydia Infections , Gonorrhea , HIV Infections , Sexually Transmitted Diseases , Syphilis , Adolescent , Adult , Aged , Anti-Bacterial Agents , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology , Chlamydia Infections/prevention & control , Communicable Disease Control , Delivery of Health Care , Gonorrhea/diagnosis , Gonorrhea/epidemiology , HIV Infections/epidemiology , Humans , Pandemics , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/prevention & control , Syphilis/epidemiology
14.
Acta Derm Venereol ; 102: adv00795, 2022 Oct 19.
Article in English | MEDLINE | ID: covidwho-2054842

ABSTRACT

The coronavirus SARS-CoV-2 (COVID-19) pandemic led to major restrictions in daily life and social contacts in Finland in March 2020. The effect of these restrictions on sexually transmitted infections (STIs) is unclear. The aim of this study was to analyse the incidence and positive rates of sexually transmitted infections in Northern Finland between 2020 and 2021 and compare these with the years prior to the pandemic. Numbers of positive Chlamydia trachomatis, HIV and hepatitis C samples were lower in 2020 to 2021 than in previous years, whereas more gonorrhoea and syphilis was found during pandemic than in previous years. The number of new cases of C. trachomatis reported each month decreased in the first months of the pandemic, but exceeded the prior pandemic-level in autumn 2020. When the mean positive sample rates were compared with the years 2015 to 2019, there was a significant decrease in positive C. trachomatis (p < 0.001) and hepatitis C (p < 0.001) sample rates in both 2020 and 2021. The positive rates for Treponema pallidum in 2020 did not differ significantly (p = 0.38) from previous years. In conclusion, these results show that sexually transmitted infections occurred despite recommendations for social distancing during the COVID-19 pandemic. Thus, easy access to STI testing should always be available, even during exceptional circumstances.


Subject(s)
COVID-19 , Chlamydia Infections , Gonorrhea , HIV Infections , Hepatitis C , Sexually Transmitted Diseases , Syphilis , Humans , COVID-19/epidemiology , Pandemics , Incidence , Finland/epidemiology , SARS-CoV-2 , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Syphilis/epidemiology , Chlamydia trachomatis , HIV Infections/diagnosis , HIV Infections/epidemiology , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology
15.
J Med Internet Res ; 24(8): e37850, 2022 08 25.
Article in English | MEDLINE | ID: covidwho-2022384

ABSTRACT

BACKGROUND: HIV and sexually transmitted infections (STIs) are major global public health concerns. Over 1 million curable STIs occur every day among people aged 15 years to 49 years worldwide. Insufficient testing or screening substantially impedes the elimination of HIV and STI transmission. OBJECTIVE: The aim of our study was to develop an HIV and STI risk prediction tool using machine learning algorithms. METHODS: We used clinic consultations that tested for HIV and STIs at the Melbourne Sexual Health Centre between March 2, 2015, and December 31, 2018, as the development data set (training and testing data set). We also used 2 external validation data sets, including data from 2019 as external "validation data 1" and data from January 2020 and January 2021 as external "validation data 2." We developed 34 machine learning models to assess the risk of acquiring HIV, syphilis, gonorrhea, and chlamydia. We created an online tool to generate an individual's risk of HIV or an STI. RESULTS: The important predictors for HIV and STI risk were gender, age, men who reported having sex with men, number of casual sexual partners, and condom use. Our machine learning-based risk prediction tool, named MySTIRisk, performed at an acceptable or excellent level on testing data sets (area under the curve [AUC] for HIV=0.78; AUC for syphilis=0.84; AUC for gonorrhea=0.78; AUC for chlamydia=0.70) and had stable performance on both external validation data from 2019 (AUC for HIV=0.79; AUC for syphilis=0.85; AUC for gonorrhea=0.81; AUC for chlamydia=0.69) and data from 2020-2021 (AUC for HIV=0.71; AUC for syphilis=0.84; AUC for gonorrhea=0.79; AUC for chlamydia=0.69). CONCLUSIONS: Our web-based risk prediction tool could accurately predict the risk of HIV and STIs for clinic attendees using simple self-reported questions. MySTIRisk could serve as an HIV and STI screening tool on clinic websites or digital health platforms to encourage individuals at risk of HIV or an STI to be tested or start HIV pre-exposure prophylaxis. The public can use this tool to assess their risk and then decide if they would attend a clinic for testing. Clinicians or public health workers can use this tool to identify high-risk individuals for further interventions.


Subject(s)
Chlamydia Infections , Gonorrhea , HIV Infections , Sexually Transmitted Diseases , Syphilis , Algorithms , Chlamydia Infections/diagnosis , Gonorrhea/diagnosis , HIV Infections/diagnosis , HIV Infections/epidemiology , HIV Infections/prevention & control , Homosexuality, Male , Humans , Internet , Machine Learning , Male , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/prevention & control , Syphilis/diagnosis
16.
Int J Environ Res Public Health ; 19(15)2022 08 05.
Article in English | MEDLINE | ID: covidwho-1979218

ABSTRACT

The social distancing measures introduced due to the COVID-19 pandemic may have affected the sexual behavior of the population. We collected data retrospectively from the National STD Center of Hungary. The overall patient influx data of the STD Center and the number of patients diagnosed with syphilis, chlamydia, and gonorrhea infections were assessed in the three-month period of 2020 when the strict governmental lockdown was introduced in Hungary. Data were compared to the pre- and post-lockdown quarters of 2020 and matched to the respective quarters of 2018 and 2019. The number of patients diagnosed with syphilis and chlamydia infections in 2020 during the lockdown decreased compared to 2018 and 2019, while the number of gonorrhea cases increased. The lower number of STI screenings resulted in a significant decrease in asymptomatic syphilis and chlamydia case numbers. However, the growing number of gonorrhea cases in 2020 during lockdown highlights that sexual behavior remained unchanged regardless of restrictions. Therefore, gonorrhea may be considered as an indicator of STI incidences during the pandemic.


Subject(s)
COVID-19 , Chlamydia Infections , Gonorrhea , HIV Infections , Sexually Transmitted Diseases , Syphilis , COVID-19/epidemiology , Chlamydia Infections/epidemiology , Communicable Disease Control , Gonorrhea/diagnosis , Gonorrhea/epidemiology , HIV Infections/epidemiology , Humans , Hungary/epidemiology , Pandemics , Retrospective Studies , Sexual Behavior , Sexually Transmitted Diseases/prevention & control , Syphilis/epidemiology
17.
Sex Transm Dis ; 49(10): 700-705, 2022 10 01.
Article in English | MEDLINE | ID: covidwho-1931960

ABSTRACT

BACKGROUND: Chlamydia is the most frequently reported sexually transmitted infection. COVID-19 exacerbated the challenges in treating and preventing new Chlamydia trachomatis (CT) infections. This study examined the impact of COVID-19 on treating CT-positive patients discharged from a safety-net women's emergency unit. METHODS: This was a preretrospective and postretrospective cohort study. Chlamydia trachomatis -positive female patients seen in the women's emergency unit were evaluated. Patients discharged in 2019, the "pre-COVID-19" group, and those discharged in 2020, the "COVID-19" group, were compared. The primary outcome was CT treatment within 30 days, and secondary outcomes included prescription dispensation, repeat tests taken, and expedited partner treatment. A subgroup of patients discharged before treatment who entered a nurse-led follow-up program was also evaluated. RESULTS: Of the 1357 cases included, there were no differences in successful 30-day treatment (709 of 789 [89.9%] vs. 568 of 511 [89.9%], P = 0.969) or repeat positive CT test (74 of 333 [22.2%] vs. 46 of 211 [21.8%]), P = 0.36) between pre-COVID-19 and COVID-19. However, the patients who picked up their prescription (196 of 249 [78.7%] vs. 180 of 206 [87.4%], P = 0.021) and those who were prescribed expedited partner therapy (156 of 674 [23.1%] vs. 292 of 460 [63.5%], P < 0.001) increased. Findings in the subgroup of patients who entered the follow-up program were consistent with those in the full cohort. CONCLUSIONS: The COVID-19 pandemic did not change treatment patterns of CT-positive patients in this safety-net women's emergency unit. However, patients were more likely to pick up their medications during COVID-19. Despite the perseverance of these programs through the pandemic, most patients are discharged before positive results, and a fair amount remain untreated.


Subject(s)
COVID-19 , Chlamydia Infections , COVID-19/epidemiology , Chlamydia Infections/drug therapy , Chlamydia Infections/epidemiology , Chlamydia Infections/prevention & control , Chlamydia trachomatis , Cohort Studies , Emergency Service, Hospital , Female , Humans , Pandemics , Patient Discharge
18.
researchsquare; 2022.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-1828548.v1

ABSTRACT

Background: Young men who have sex with men (MSM), are a key population at high risk of sexually transmitted infections (STIs) yet are often underrepresented in research in settings where same sex sexual behavior is criminalized. We conducted a respondent-driven sampling (RDS) bio-behavioral survey to estimate the prevalence of five curable STIs: Chlamydia trachomatis (CT) , Mycoplasma genitalium (MG) , Neisseria gonorrhea (NG) , Trichomonas vaginalis (TV) and syphilis, and associated risk factors among tertiary student MSM (TSMSM) in Nairobi, Kenya. Methods Between February and March 2021, we recruited 248 TSMSM aged ≥ 18 years who self-reported engaging in anal and/or oral sex with another man in the past year. Samples collected included urine, provider-collected anorectal and oropharyngeal swabs for pooled CT/MG/NG/TV testing using multiplex nucleic acid amplification tests (NAATs), and venous blood for serological syphilis screening using Rapid plasma reagin (RPR) followed by Treponema pallidum haemagglutination assay (TPHA) for confirmation of current infection. Participants self-completed a behavioral survey on REDCap digital platform. Data analysis was done using RDS-Analyst (v0.72) and Stata (v15). Differences in proportions were examined using the chi-square (X 2 ) test, and unweighted multivariate logistic regression was used to assess factors associated with STI prevalence. Results RDS-adjusted prevalence of STIs was: at least one of five STI: 58.8%, 95% confidence interval (CI): 50.4–67.3%, CT: 51.0%, 95% CI: 42.3–59.8%, NG: 11.3%, 95% CI: 6.1–16.5%, MG: 6.0%, 95% CI: 2.6–9.4%, TV: 1.5%, 95% CI: − .3-3.3% and latent syphilis: 0.7%, 95 CI: -0.1-1.5%. Frequency of co-infection with more than one STI was: CT/NG: 5.7%, 95% CI: 2.7–8.7%, CT/MG: 4.5%, 95% CI: 2.3–6.7% and MG/NG = CT/MG/NG: 1.7%, 95% CI: 0.1–3.3%. Factors independently associated with STI prevalence were inconsistent condom use during anal sex with a man in the 12 months preceding the survey (adjusted odds ratio [AOR] = 1.89, 95% CI: 1.03–3.47, p = 0.038) and the last sex partner being a regular partner (AOR = 2.35, 95% CI: 1.12–4.92, p = 0.023). Conclusion STI prevalence among TSMSM in Nairobi is disturbingly high and is associated with inconsistent condom use and having a regular sex partner. Tailored STI testing, treatment and prevention interventions are urgently needed for this population.


Subject(s)
Mycoplasma Infections , Gonorrhea , Chlamydia Infections
19.
Sex Transm Dis ; 49(7): 490-496, 2022 07 01.
Article in English | MEDLINE | ID: covidwho-1891201

ABSTRACT

BACKGROUND: During the COVID-19 pandemic, disruptions were anticipated in the US health care system for routine preventive and other nonemergency care, including sexually transmitted infection care. METHODS: Using a large national laboratory data set, we assessed the impact of the COVID-19 pandemic on the weekly numbers and percent positivity of chlamydia and gonorrhea tests ordered from the 5th week of 2019 to the 52nd week of 2020 in the United States. We compared weekly 2020 values for test volume, percent positive, and number of positives with the same week in 2019. We also examined the potential impact of stay-at-home orders for the month of April 2020. RESULTS: Immediately after the declaration of a national emergency for COVID-19 (week 11, 2020), the weekly number of gonorrhea and chlamydia tests steeply decreased. Tests then rebounded toward the 2019 pre-COVID-19 level beginning the 15th week of 2020. The weekly percent positive of chlamydia and gonorrhea remained consistently higher in 2020. In April 2020, the overall number of chlamydia tests was reduced by 53.0% (54.1% in states with stay-at-home orders vs. 45.5% in states without stay-at-home orders), whereas the percent positive of chlamydia and gonorrhea tests increased by 23.5% and 79.1%, respectively. CONCLUSIONS: To limit the impact of the pandemic on control of chlamydia and gonorrhea, public health officials and health care providers can assess measures put in place during the pandemic and develop new interventions to enable care for sexually transmitted infections to be delivered under pandemic and other emergency conditions. The assessment like this study is continuously needed.


Subject(s)
COVID-19 , Chlamydia Infections , Gonorrhea , Sexually Transmitted Diseases , COVID-19/diagnosis , COVID-19/epidemiology , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology , Chlamydia Infections/prevention & control , Chlamydia trachomatis , Gonorrhea/diagnosis , Gonorrhea/epidemiology , Gonorrhea/prevention & control , Humans , Pandemics/prevention & control , Sexually Transmitted Diseases/epidemiology , United States/epidemiology
20.
Am J Public Health ; 112(7): 985-989, 2022 07.
Article in English | MEDLINE | ID: covidwho-1865380

ABSTRACT

The Baltimore City Health Department (Baltimore, MD) promoted IWantTheKit for chlamydia, gonorrhea, and HIV testing to city residents and clinic patients when COVID-19 restricted in-person clinic services. From April to October 2020, monthly online IWantTheKit orders increased by 645%. A high prevalence of chlamydia and gonorrhea was detected, and 96% of users who tested positive for chlamydia and gonorrhea were successfully contacted for treatment. Uptake by Baltimore City Health Department priority populations and excellent treatment linkage demonstrated how a public health-academic partnership successfully addressed a service gap during the pandemic. (Am J Public Health. 2022;112(7):985-989. https://doi.org/10.2105/AJPH.2022.306835).


Subject(s)
COVID-19 , Chlamydia Infections , Chlamydia , Gonorrhea , HIV Infections , COVID-19/diagnosis , COVID-19/epidemiology , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology , Gonorrhea/diagnosis , Gonorrhea/epidemiology , HIV Infections/diagnosis , HIV Infections/epidemiology , Humans
SELECTION OF CITATIONS
SEARCH DETAIL